Cardiac myosin (inhibitor) drugs for Hypertrophic Cardiomyopathy
3 tracked Cardiac myosin (inhibitor) drugs in the Hypertrophic Cardiomyopathy race. The class explanation lives on the Cardiac myosin (inhibitor) page; the full indication pipeline across every mechanism is on the Hypertrophic Cardiomyopathy page.
2 approved / phase 41 Phase 3
Head-to-head evidence: Aficamten vs HRS-1893 · Aficamten vs Mavacamten · HRS-1893 vs Mavacamten